Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Journey Medical Corporation (DERM : NSDQ)
 
 • Company Description   
Journey Medical Corporation is a commercial-stage pharmaceutical company. It focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Journey Medical Corporation is based in Scottsdale, Arizona.

Number of Employees: 41

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.71 Daily Weekly Monthly
20 Day Moving Average: 126,061 shares
Shares Outstanding: 27.14 (millions)
Market Capitalization: $209.22 (millions)
Beta: 0.81
52 Week High: $9.40
52 Week Low: $3.54
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -1.28% -1.11%
12 Week 2.12% 0.47%
Year To Date 0.00% 0.00%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9237 E VIA DE VENTURA BLVD. SUITE 105
-
SCOTTSDALE,AZ 85258
USA
ph: 480-434-6670
fax: -
ir@jmcderm.com http://www.jmcderm.com
 
 • General Corporate Information   
Officers
Claude Maraoui - Chief Executive Officer; President and Director
Lindsay A. Rosenwald - Executive Chairman
Joseph Benesch - Chief Financial Officer
Neil Herskowitz - Director
Justin Smith - Director

Peer Information
Journey Medical Corporation (GSAC)
Journey Medical Corporation (CASI)
Journey Medical Corporation (ALCD.)
Journey Medical Corporation (OMNN)
Journey Medical Corporation (CGPI.)
Journey Medical Corporation (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 48115J109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 03/25/26
Share - Related Items
Shares Outstanding: 27.14
Most Recent Split Date: (:1)
Beta: 0.81
Market Capitalization: $209.22 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.27 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/25/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 28.56
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 7.85
Price/Cash Flow: -
Price / Sales: 3.52
EPS Growth
vs. Year Ago Period: 25.00%
vs. Previous Quarter: 43.75%
Sales Growth
vs. Year Ago Period: 20.52%
vs. Previous Quarter: 17.47%
ROE
12/31/25 - -
09/30/25 - -39.94
06/30/25 - -48.69
ROA
12/31/25 - -
09/30/25 - -10.45
06/30/25 - -11.26
Current Ratio
12/31/25 - -
09/30/25 - 1.42
06/30/25 - 1.27
Quick Ratio
12/31/25 - -
09/30/25 - 1.12
06/30/25 - 0.95
Operating Margin
12/31/25 - -
09/30/25 - -14.58
06/30/25 - -15.49
Net Margin
12/31/25 - -
09/30/25 - -14.58
06/30/25 - -15.49
Pre-Tax Margin
12/31/25 - -
09/30/25 - -14.38
06/30/25 - -15.28
Book Value
12/31/25 - -
09/30/25 - 0.98
06/30/25 - 0.82
Inventory Turnover
12/31/25 - -
09/30/25 - 1.56
06/30/25 - 1.46
Debt-to-Equity
12/31/25 - -
09/30/25 - 0.75
06/30/25 - 1.11
Debt-to-Capital
12/31/25 - -
09/30/25 - 43.00
06/30/25 - 52.60
 

Powered by Zacks Investment Research ©